Statistics

Total Visits

Views
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials.34

Select a period of time:

Number of views in the range

Views
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials.27

Views

Views
November 20240
December 20240
January 20250
February 20250
March 202516
April 202511
May 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore16
Hong Kong10
Spain1
 

Top cities views

Views
Hong Kong10